TULKROSSI Trademark
Trademark Overview
On Friday, December 23, 2022, a trademark application was filed for TULKROSSI with the United States Patent and Trademark Office. The USPTO has given the TULKROSSI trademark a serial number of 97730485. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, January 12, 2026. This trademark is owned by Turning Point Therapeutics, Inc.. The TULKROSSI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
General Information
| Serial Number | 97730485 |
| Word Mark | TULKROSSI |
| Filing Date | Friday, December 23, 2022 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Monday, January 12, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 28, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 29, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Turning Point Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Turning Point Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
Trademark Events
| Event Date | Event Description |
| Tuesday, December 27, 2022 | NEW APPLICATION ENTERED |
| Thursday, December 29, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 23, 2023 | ASSIGNED TO EXAMINER |
| Saturday, September 23, 2023 | NON-FINAL ACTION WRITTEN |
| Saturday, September 23, 2023 | NON-FINAL ACTION E-MAILED |
| Saturday, September 23, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, December 14, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, December 14, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, December 15, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 24, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 8, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 28, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 28, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 23, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, January 7, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, January 7, 2025 | SOU EXTENSION 1 FILED |
| Tuesday, January 7, 2025 | SOU EXTENSION 1 GRANTED |
| Tuesday, March 4, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, June 24, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, June 24, 2025 | SOU EXTENSION 2 FILED |
| Tuesday, June 24, 2025 | SOU EXTENSION 2 GRANTED |
| Tuesday, June 24, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, January 12, 2026 | SOU TEAS EXTENSION RECEIVED |
| Monday, January 12, 2026 | SOU EXTENSION 3 FILED |
| Monday, January 12, 2026 | SOU EXTENSION 3 GRANTED |
| Monday, January 12, 2026 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
